Michelle Gilson
Stock Analyst at Morgan Stanley
(1.07)
# 3,876
Out of 5,150 analysts
32
Total ratings
31.03%
Success rate
-6.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintains: Overweight | $20 → $24 | $9.56 | +151.05% | 5 | Feb 24, 2026 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $35.69 | -15.94% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $3.28 | +418.29% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $241.38 | -18.80% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $28.18 | +59.69% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $34.42 | +120.80% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $60.43 | +50.59% | 12 | Mar 1, 2021 |
Vir Biotechnology
Feb 24, 2026
Maintains: Overweight
Price Target: $20 → $24
Current: $9.56
Upside: +151.05%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $35.69
Upside: -15.94%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $3.28
Upside: +418.29%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $241.38
Upside: -18.80%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $28.18
Upside: +59.69%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $34.42
Upside: +120.80%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $60.43
Upside: +50.59%